慢性腎臓病の脂質管理のためのKDIGO診療ガイドライン

出版社： 東京医学社
著者：
発行日： 2014-07-10
分野： 臨床医学：内科  >  腎臓
ISBN： 9784885632372
電子書籍版： 2014-07-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

1,980 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,980 円(税込)

購入する

商品紹介

すべての慢性腎臓病患者における脂質管理と治療に関する最新のガイダンスを提供するガイドライン。各条文ごとにＧＲＡＤＥ法に準拠したエビデンスの質の評価と推奨事項の強度、理論的根拠、重要事項、研究推奨事項等を示す。

目次

  • 慢性腎臓病の脂質管理のためのKDIGO診療ガイドライン

    ―目次―

    1章　CKDを有する成人における脂質状態の評価
    2章　成人における薬物によるコレステロール低下療法
    3章　CKDのある小児における脂質状態の評価
    4章　小児におけるコレステロール低下薬物治療
    5章　成人におけるトリグリセライド低下療法
    6章　小児におけるトリグリセライド低下療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

References

P.47 掲載の参考文献
1. National Kidney Foundation. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003 ; 41 : S1-92.
 
2. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007 ; 49 : S1-180.
 
3. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998 ; 32 : S142-156.
PubMed
4. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol : executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995 ; 41 : 1414-1420.
 
5. Stein EA, Myers GL. National Cholesterol Education Program recommendations for triglyceride measurement : executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995 ; 41 : 1421-1426.
 
6. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol : executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995 ; 41 : 1427-1433.
 
7. National Heart Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents : summary report. Pediatrics 2011 ; 128 (Suppl 5) : S213-256.
 
8. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets : an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012 ; 5 : 2-5.
 
9. Takahashi O, Glasziou PP, Perera R et al. Lipid re-screening : what is the best measure and interval? Heart 2010 ; 96 : 448-452.
PubMed
10. Glasziou PP, Irwig L, Heritier S et al. Monitoring cholesterol levels : measurement error or true change? Ann Intern Med 2008 ; 148 : 656-661.
PubMed
11. Jafri H, Karas RH, Alsheikh-Ali AA. Meta-analysis : Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010 ; 153 : 800-808.
PubMed
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285 : 2186-2197.
 
13. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes : a meta-analysis. J Am Soc Nephrol 2006 ; 17 : 2006-2016.
PubMed
14. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 2011 ; 377 : 2181-2192.
PubMed
15. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure : a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007 ; 370 : 1829-1839.
PubMed
16. Chiang CK, Ho Tl, Hsu SP et al. Low-density lipoprotein cholesterol : association with mortality and hospitalization in hemodialysis patients. Blood Purif 2005 ; 23 : 134-140.
 
17. Coresh J, Longenecker JC, Miller III ER et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998 ; 9 : S24-S30.
 
18. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002 ; 61 : 1887-1893.
 
19. Lowrie EG, Lew NL. Death risk in hemodialysis patients : the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990 ; 15 : 458-482.
 
20. Krane V, Winkler K, Drechsler C et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am J Kidney Dis 2009 ; 54 : 902-911.
PubMed
21. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients : role of inflammation and malnutrition. JAMA 2004 ; 291 : 451-59.
 
22. Tonelli M, Muntner P, Lloyd A et al. Association between LDL-C and Risk of Myocardial Infarction in CKD. J Am Soc Nephrol 2013 ; 24 : 979-986.
 
23. Grundy SM. Diabetes and coronary risk equivalency : what does it mean? Diabetes Care 2006 ; 29 : 457-460.
PubMed
24. Cooper A, Nherera L, Calvert N et al. Clinical Guidelines and Evidence Review for Lipid Modification : Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. Lipid Modification : Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, 2008.
 
25. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice : full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 ; 14 (Suppl 2) : S1-113.
 
26. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias : the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 ; 32 : 1769-1818.
 
27. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes : a population-level cohort study. Lancet 2012 ; 380 : 807-814.
PubMed
28. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998 ; 339 : 799-805.
PubMed
29. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 ; 351 : 1285-1295.
PubMed
30. Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004 ; 44 : 1587-1592.
PubMed
31. Latif F, Kleiman NS, Cohen DJ et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents : a report from the EVENT (Evaluation of Drug Eluting Stents and ischemic Events) registry. JACC Cardiovasc Interv 2009 ; 2 : 37-45.
PubMed
32. Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease : the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008 ; 51 : 1448-1454.
PubMed
33. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study : a post-hoc analysis. Lancet 2010 ; 376 : 1916-1922.
PubMed
34. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons With chronic kidney disease : A systematic review and meta-analysis. Ann Intern Med 2012 ; 157 : 263-275.
PubMed
35. Colhoun HM, Betteridge DJ, Durrington PN et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes : an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009 ; 54 : 810-819.
PubMed
36. Tonelli M, Jose P, Curhan G et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease : analysis of a previously conducted randomised trial. BMJ 2006 ; 332 : 1426.
PubMed
37. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004 ; 110 : 2809-2816.
PubMed
38. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 ; 97 : 1837-1847.
PubMed
39. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012 ; 33 : 1635-1701.
 
40. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002 ; 105 : 310-315.
PubMed
41. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment : the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007 ; 93 : 172-176.
PubMed
42. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales : prospective derivation and validation of QRISK2. BMJ 2008 ; 336 : 1475-1482.
PubMed
43. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 ; 353 : 238-248.
PubMed
44. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 ; 360 : 1395-1407.
PubMed
45. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons With chronic kidney disease : A systematic Review and meta-analysis. Ann Intern Med 2012 ; 157 : 251-262.
PubMed
46. Hou W, Lv J, Perkovic V et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease : a systematic review and meta-analysis. Eur Heart J 2013 ; 34 : 1807-1817.
 
47. Marz W, Genser B, Drechsler C et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011 ; 6 : 1316-1325.
PubMed
48. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients : a multicentre, randomised, placebo-controlled trial. Lancet 2003 ; 361 : 2024-2031.
PubMed
49. Pilmore H, Dent H, Chang S et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010 ; 89 : 851-857.
PubMed
50. Saito Y, Goto Y, Dane A et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atherosder Thromb 2003 ; 10 : 329-336.
PubMed
51. Saito Y, Goto Y, Nakaya N et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis 1988 ; 72 : 205-211.
PubMed
52. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 2006 ; 368 : 1155-1163.
PubMed
53. Nakamura H, Mizuno K, Ohashi Y et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009 ; 206 : 512-517.
PubMed
54. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998 ; 32 : S112-119.
PubMed
55. Srinivasan SR, Myers L, Berenson GS. Distribution and correlates of non-high-density lipoprotein cholesterol in children : the Bogalusa Heart Study. Pediatrics 2002 ; 110 : e29.
PubMed
56. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults : implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999 ; 281 : 727-735.
 
57. Berenson GS, Srinivasan SR, Bao W et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998 ; 338 : 1650-1656.
 
58. Magnussen CG, Raitakari OT, Thomson R et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood : evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 2008 ; 117 : 32-2.
PubMed
59. Schrott HG, Bucher KA, Clarke WR et al. The Muscatine hyperlipidemia family study program. Prog Clin Biol Res 1979 ; 32 : 619-646.
PubMed
60. Jarvisalo MJ, Jartti L, Nanto-Salonen K et al. Increased aortic intimamedia thickness : a marker of preclinical atherosclerosis in high-risk children. Circulation 2001 ; 104 : 2943-2947.
PubMed
61. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients : a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science ; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease ; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research : endorsed by the American Academy of Pediatrics. Circulation 2006 ; 114 : 2710-2738.
 
62. Olson RE. Atherogenesis in children : implications for the prevention of atherosclerosis. Adv Pediatr 2000 ; 47 : 55-78.
PubMed
63. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease : epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002 ; 14 : 197-204.
PubMed
64. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007 ; 22 : 1095-1112.
PubMed
65. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD : 2008 update. Am J Kidney Dis 2009 ; 53 : S1-124.
 
66. USRDS. US Renal Data System, USRDS 2003 Annual Data Report : Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, 2004.
 
67. Kwiterovich PO Jr, Barton BA, McMahon RP et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty : the Dietary Intervention Study in Children (DISC). Circulation 1997 ; 96 : 2526-2533.
PubMed
68. Niinikoski H, Koskinen P, Punnonen K et al. Intake and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol : the STRIP baby study. Special Turku Coronary Risk Factor Intervention Project for Babies. Am J Clin Nutr. 1997 ; 66 : 569-574.
PubMed
69. Niinikoski H, Lapinleimu H, Viikari J et al. Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. Pediatrics 1997 ; 99 : 687-694.
 
70. Niinikoski H, Viikari J, Ronnemaa T et al. Regulation of growth of 7- to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial. Pediatrics 1997 ; 100 : 810-816.
PubMed
71. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996 ; 10 : 171-174.
PubMed
72. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P et al. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol 2009 ; 24 : 1205-1210.
PubMed
73. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome : the effect of statin therapy. J Pediatr 1997 ; 130 : 470-474.
PubMed
74. Yoshimura N, Oka T, Okamoto M et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992 ; 53 : 94-99.
PubMed
75. Avis HJ, Hutten BA, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010 ; 55 : 1121-1126.
PubMed
76. Clauss SB, Holmes KW, Hopkins P et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005 ; 116 : 682-688.
PubMed
77. de Jongh S, Lilien MR, op't Roodt J et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Call Cnadiol 2002 : 40 : 2117-2121.
 
78. de Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia : a randomized, doubleblind, placebo-controlled trial with simvastatin. Circulation 2002 ; 106 : 2231-2237.
PubMed
79. Knipscheer HC, Boelen CC, Kastelein JJ et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996 ; 39 : 867-871.
PubMed
80. Lambert M, Lupien PJ, Gagne C et al. Treatment of familial hypercholesterolemia in children and adolescents : effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996 ; 97 : 619-628.
 
81. McCrindle BW, Helden E, Cullen-Dean G et al. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002 ; 51 : 715-721.
PubMed
82. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia : a multicenter, randomized, placebo-controlled trial. J Pediatr 2003 ; 143 : 74-80.
PubMed
83. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia : the younger, the better. Circulation 2007 ; 116 : 564-668.
 
84. Stein EA, lllingworth DR, Kwiterovich PO Jr et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia : a randomized controlled trial. JAMA 1999 ; 281 : 137-144.
 
85. van der Graaf A, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008 ; 52 : 1421-1429.
PubMed
86. van der Graaf A, Nierman MC, Firth JC et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Acta Paediatr 2006 ; 95 : 1461-1466.
PubMed
87. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia : a randomized controlled trial. JAMA 2004 ; 292 : 331-337.
PubMed
88. Preiss D, Tikkanen MJ, Welsh P et al. Lipid-modifying therapies and risk of pancreatitis : a meta-analysis. JAMA 2012 ; 308 : 804-811.
PubMed
89. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 ; 376 : 1670-1671.
PubMed
90. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes : a systematic review and meta-analysis. Lancet 2010 ; 375 : 1875-1884.
PubMed
91. Tonelli M, Collins D, Robins S et at. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004 ; 66 : 1123-1130.
PubMed
92. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes : results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005 ; 45 : 485-93.
 
93. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 2005 ; 366 : 1849-1861.
 
94. Ting RD, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment : the FIELD Study. Diabetes Care 2012 ; 35 : 218-225.
PubMed
95. Davis TM, Ting R, Best JD et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus : the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011 ; 54 : 280-290.
PubMed
96. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-1574.
PubMed
97. Zhao YY, Weir MA, Manno M et al. New fibrate use and acute renal outcomes in elderly adults a population-based study. Ann Intern Med 2012 ; 156 : 560-569.
PubMed
98. Chen HH, Lin LH. Recurrent pancreatitis secondary to type V hyperlipidemia : report of one case. Acta Paediatr Taiwan 2000 ; 41 : 276-278.
PubMed
99. Spratt P, Esmore D, Keogh A et at. Comparison of three immunosuppressive protocols in cardiac transplantation. Transplant Proc 1989 ; 21 : 2481-2483.
PubMed
100. Chicaud P, Demange J, Drouin P et al. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. Presse Med 1984 ; 13 : 417-419.
PubMed
101. Steinmetz J, Morin C, Panek E et al. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981 ; 112 : 43-53.
 
102. Wheeler KA, West RJ, Lloyd JK et al. Double blind trial of bezafibrate in familial hypercholesterolemia. Arch Dis Child 1985 ; 60 : 34-37.
PubMed
103. Cerkauskiene R, Kaminskas A, Kaltenis P et al. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome]. Medicina 2003 ; 39 (Suppl 1) : 82-87.
 
104. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U et al. Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. J Med Assoc Thai 1999 ; 82 (Suppl 1) : S122-S128.
 
105. Goren A, Stankiewicz H, Goldstein R et al. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics 1991 ; 88 : 265-268.
PubMed
106. Hogg RJ, Lee J, Nardelli N et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy : report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006 ; 1 : 467-474.
 
107. Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5 : grading the strength of a body of evidence when comparing medical interventionsagency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010 ; 63 : 513-523.
 
108. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004 ; 328 : 1490.
PubMed
109. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008 ; 336 : 1049-1051.
PubMed
110. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 2006 ; 70 : 2058-2065.
PubMed
111. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines : the AGREE project. QuaI Saf Health Care 2003 ; 12 : 18-23.
 
112. Shiftman RN, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines : a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003 ; 139 : 493-198.
 
113. Institute of Medicine. Finding What Works in Health Care : Standards for Systematic Reviews. The National Academies Press : Washington, DC, 2011.
 
114. Institute of Medicine. Clinical Practice Guidelines We Can Trust. National Academies Press : Washington, DC, 2011.
PubMed

書評

最近チェックした商品履歴

Loading...